Acute kIDnEy injury in coviD-19 (AIDED)
Research type
Research Study
Full title
Long-term outcomes after Acute Kidney Injury in coronavirus disease (COVID-19)
IRAS ID
290084
Contact name
Nitin V Kolhe
Contact email
Sponsor organisation
University Hospitals of Derby and Burton NHS Foundation Trust
Clinicaltrials.gov Identifier
N/A , N/A
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Research Summary:
When people get COVID-19, some also develop a complication called acute kidney injury (AKI), where the kidneys suddenly stop working properly. This happens in about 5–35% of COVID patients. Unfortunately, the outlook is much worse when AKI happens in COVID: up to 60% of these patients die, compared to about 10–20% when AKI is caused by something else.
COVID seems to damage the kidneys in a different way than other illnesses. In many patients, early warning signs like protein or blood in the urine show up, but full-blown AKI often comes later in the hospital stay, and it tends to be more serious. More people with COVID-related AKI need dialysis (a machine that does the kidney’s job).
In general, AKI can cause lasting kidney damage. Up to 1 in 4 survivors of non-COVID AKI develop chronic kidney disease (CKD), which raises the risk of heart problems, kidney failure, and death. There are concerns that COVID-related AKI might lead to even more long-term problems, which could put extra pressure on the health system. While there are follow-up guidelines for COVID-related lung problems, there aren’t any for kidney problems.
The study aimed to understand if kidney function gets worse in the long run more often after COVID-related AKI than after COVID with no kidney involvementThis study will investigate the effects of acute kidney injury (AKI; a sudden reduction in kidney function) on the irreversible deterioration in kidney function and the factors associated with this in people who have been treated in hospital for COVID-19. We have seen that many people who have had more severe forms of COVID-19 have also had AKI. It is important to understand the effects of AKI due to COVID-19 on kidney function so we can decide how best to monitor and treat patients in this situation.
The study will recruit people who had COVID-19, were admitted to hospital and developed AKI during their hospital stay. We will compare data from this cohort with an existing study database that contains data on people who have had AKI due to non-COVID-19 causes (participants recruited between 2013 and 2016).
We will also recruit a cohort of people with COVID-19 and who did not develop AKI during their hospital admission. The justification for including this group is that people with COVID-19 have a high rate of kidney abnormalities that may indicate subclinical AKI (i.e. evidence of kidney injury without a change in serum creatinine), and therefore a lack of clinically detected AKI doesn’t mean that this group does not have a risk of long-term kidney damage. Study of this group, alongside a COVID-AKI group, will allow this to be assessed.
For the two groups – COVID AKI and COVID non-AKI, information from their medical records about their hospital admission with COVID-19 will be collected. Weight, height and blood pressure measurements, blood and urine tests, and a study questionnaire with details of medical events since last study follow-up, hospital re-admissions and current medications will be performed at recruitment, 6 and 12 months after hospital discharge.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
20/EM/0262
Date of REC Opinion
30 Nov 2020
REC opinion
Further Information Favourable Opinion